Enfusion Expects 2024 Revenue of $200M-$210M Vs $202.3M Est

Financial outlook 13 These statements are forward-looking and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. A reconciliation of these forward looking non-GAAP measures to the corresponding GAAP measure is not available without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, Enfusion is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results. Adjusted EBITDA guidance excludes stock-based compensation of  $19-20 million for the full year 2024, of which we estimate approximately 1/3 will occur in 1Q24. FCF Conversion is Adjusted Free Cash Flow divided by Adjusted EBITDA 2024E Revenue $200-$210 million Adjusted EBITDA $40-45 million FCF Conversion 50-55%